CA-DANTE-LABS
Dante Labs today announced that it has begun installing Illumina next generation sequencing (NGS) technology at its new European headquarters in Italy to make whole genome sequencing (WGS) and whole exome sequencing (WES) available and accessible to individuals around the world through its global direct-to-consumer genomics platform. Sequencing will be carried out using Illumina’s most powerful sequencer, the NovaSeq™ 6000 System, providing high throughput genomic testing.
Andrea Riposati, Chief Executive Officer of Dante Labs, said: “We are delighted to work with Illumina’s leading platform technology to help more people around the world make informed decisions about their lifestyle and health based on the knowledge of their genome. We currently offer the only test that analyses 100% of people’s DNA. Through the stories of our users, we witness the transformative power of genomics every day, for individuals as well as for society as a whole. This is only the beginning.”
Paula Dowdy, Senior Vice President and General Manager, Commercial Operations, Europe, Middle East and Africa at Illumina, said: “We are pleased that Dante Labs has selected Illumina technology to provide WGS at a premium depth of coverage and rapid turnaround time. We share their vision of positively influencing personal healthcare by unlocking the power of the genome.”
Dante Labs’ WGS-based test kits are purchased online and the DNA sample is provided by spitting saliva into a small tube that is mailed back to the company. Proprietary bioinformatics analysis interprets the meaning of specific genetic variations and reports are delivered in an easy-to-understand, user-friendly format. Customers can gain knowledge of their predisposition to developing diseases such as hereditary cancers, heart failure, diabetes and other metabolic diseases, Alzheimer’s Disease, Parkinson’s Disease, autism and other common conditions. Testing can also inform people about their ability to metabolise certain medicines and can support the journey of individuals with rare and undiagnosed genetic diseases. More broadly, Dante Lab’s genomic analysis can help people make decisions about their diet, wellness and lifestyle.
Dante Labs selected Illumina sequencers for its growth based on Illumina’s role as a pioneer in advancing genomic technologies and applications combined with a reputation for accuracy, consistency and unsurpassed local technical support.
About Dante Labs
Dante Labs’ mission is to make the most advanced genomic tests accessible to everyone. To-date, it has customers in more than 80 countries who have personally experienced the power of the whole genome. Its global whole genome sequencing platform enables individuals to access actionable insights on their predispositions, reaction to medications and personalised medicine everywhere in the world. To learn more or to purchase a Dante Labs whole genome sequencing test, visit www.dantelabs.com and follow @DanteLabs.
Source: Dante Labs
View source version on businesswire.com: https://www.businesswire.com/news/home/20191003005322/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Delivers Record First Quarter Net Sales of 1.129 Billion USD, Including Strong Performance From Two Launches With Blockbuster Potential, and Confirms Full-Year Guidance24.4.2025 07:00:00 CEST | Press release
Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first quarter of 2025. Net sales: Achieved 1,129 million USD in net sales, up 8.3% year-on-year on a constant currency basis, primarily driven by volume, complemented by favorable mix Results ahead of expectations: Net sales benefited from focused execution, favorable phasing in Injectable Aesthetics, and stronger than expected ramp-up of Nemluvio Broad-based growth: Strong performance momentum across product categories and across geographies, with constant currency year-on-year growth of 9.9% for Injectable Aesthetics, 7.8% for Dermatological Skincare, and 4.9% for Therapeutic Dermatology, which includes net sales of 39 million USD for Nemluvio® (nemolizumab) Innovation, science and education leadership: Further advanced its category leadership in dermatology: with the launch of Nemluvio and Relfydess™ (RelabotulinumtoxinA),
Engelhart and e.optimum Strengthen Their Partnership With a Further Onshore Wind PPA, Supporting Germany’s Energy Transition24.4.2025 07:00:00 CEST | Press release
The Global Commodities and Renewable Energy Trader, Engelhart, is delighted to announce the signing of a further power purchase agreement (PPA) with e.optimum, one of Germany’s largest independent energy suppliers. Following the first PPA signed in January 2025, this new agreement secures renewable electricity from additional onshore wind turbines with a total capacity of approximately 167 MWfromJuly to December 2025. This is enough green power to supply around 31,000 households. This second PPA marks a significant expansion of the partnership between the two companies. It represents a 195% increase in contracted capacity, bringing the total from 86 MW to 253 MW of onshore wind power. Furthermore, the agreement contributes directly to Germany’s transition to a net zero-carbon economy by 2045. Matthias Seel, Senior Originator Corporate Customers Europe at Engelhart, commented: "The second PPA with e.optimum is another milestone in our joint partnership. Especially in uncertain economic
Textron Aviation Raises the Bar for Workforce Development With State-of-the-Art Career & Learning Center23.4.2025 22:00:00 CEST | Press release
Textron Aviation Inc. a Textron Inc. (NYSE: TXT) company, today announced its new Career & Learning Center is complete and fully operational serving prospective, current and future Textron Aviation employees. Strategically located on the company’s East Wichita Campus, this state-of-the-art facility expands the training footprint to more than 75,000 square feet and provides a world-class employee experience during the application, hiring, onboarding and training processes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250423874476/en/ Textron Aviation Career and Learning Center | Textron Aviation “The Textron Aviation Career & Learning Center is an important investment in building the next generation of aviation manufacturing, support and professional talent,” said Ron Draper, president and CEO. “Recruiting, hiring and training a world-class workforce is vital to our ability to provide the best aviation experience for our cu
TSMC Unveils Next-Generation A14 Process at North America Technology Symposium23.4.2025 20:40:00 CEST | Press release
Showcasing TSMC’s latest offerings for high performance computing, smartphone, automotive, and IoT applications TSMC (TWSE: 2330, NYSE: TSM) today unveiled its next cutting-edge logic process technology, A14, at the Company’s North America Technology Symposium. Representing a significant advancement from TSMC’s industry-leading N2 process, A14 is designed to drive AI transformation forward by delivering faster computing and greater power efficiency. It is also expected to enhance smartphones by improving their on-board AI capabilities, making them even smarter. Planned to enter production in 2028, the current A14 development is progressing smoothly with yield performance ahead of schedule. Compared with the N2 process, which is about to enter volume production later this year, A14 will offer up to 15% speed improvement at the same power, or up to 30% power reduction at the same speed, along with more than 20% increase in logic density. Leveraging the Company’s experience in design-tech
Veracode Delivers End-to-End Risk Coverage with New Tools: AI-Powered Dynamic Analysis Security Testing with External Attack Surface Management23.4.2025 17:42:00 CEST | Press release
Seamless Integration and Speed: Latest Innovations Empower Faster, Smarter, and Safer Software Security Veracode, a global leader in application risk management, today announced new capabilities to help organizations address emerging threats, giving security professionals better visibility and control in one place. The launch includes new AI-powered functionality in the Dynamic Application Security Testing (DAST)product and an External Attack Surface Management (EASM) capability. Together, they enable security teams to discover their entire attack surface and prioritize the most critical risk to streamline and simplify security scanning. “Security teams need to see and secure everything; not only what is inside their perimeter,” said Derek Maki, Head of Product at Veracode. “With our latest DAST capabilities and Application Risk Management platform enhancements, we’re helping organizations shift from vulnerability scanning to holistic risk management, to better identify risk residing i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom